Anacor Pharmaceutica (ANAC) 99.06 $ANAC
Hercules Provides Portfolio Update for Q2 2016 and Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy
BusinessWire - Tue Jul 05, 10:34AM CDT
--Over $6.0 Billion in Total Debt Commitments Milestone achieved (since inception December 2003)
CPXX: 30.24 (-0.01), HTGC: 12.50 (+0.03), GCI: 13.81 (+0.43), PFE: 36.12 (+0.35), JAZZ: 139.88 (+1.40), ANAC: 99.06 (-0.14), RLOC: 4.56 (-0.01), EACQ: 9.90 (-0.01)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), NVAX: 7.62 (+0.16), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), EXEL: 8.15 (+0.01)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Stock Market News for May 23, 2016
Zacks Equity Research - Zacks Investment Research - Mon May 23, 9:10AM CDT
Benchmarks closed in positive territory on Friday following speculations that indications of a Fed rate hike signal that the economy may be strengthening
TSLA: 216.78 (+0.84), HD: 134.34 (+3.18), FB: 117.24 (+1.39), PFE: 36.12 (+0.35), WMT: 73.84 (+0.31), INTC: 34.00 (+0.80), GS: 150.38 (+3.38), IBM: 154.46 (+1.86), AMAT: 24.93 (+0.64), TGT: 71.31 (+1.22), ANAC: 99.06 (-0.14), GOOGL: 717.78 (+10.52), FL: 57.41 (+2.06), BRK.B: 143.65 (+1.74), AAPL: 96.68 (+0.74)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc.
BusinessWire - Fri May 20, 9:10PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company"
(Nasdaq: ANAC) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer".
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into Whether the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share is Fair to Shareholders
BusinessWire - Fri May 20, 3:43PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
ANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Anacor Pharmaceuticals, Inc. (ANAC) Over the Proposed Sale of the Company to Pfizer Inc.
BusinessWire - Fri May 20, 1:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company" (Nasdaq:ANAC) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $5.2 billion.
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 62.10 (-0.64), TTPH: 4.49 (+0.11), TRVN: 7.13 (+0.19), ADRO: 12.66 (+0.22), ANAC: 99.06 (-0.14)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.40 (+0.08), ARLZ: 3.61 (+0.05), ANAC: 99.06 (-0.14), ATHX: 2.29 (+0.05)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc. -ANAC
PR Newswire - Thu May 19, 9:10PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company" (Nasdaq- ANAC-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer".
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 62.10 (-0.64), TRVN: 7.13 (+0.19), TTPH: 4.49 (+0.11), VRTX: 88.96 (-1.09), ADRO: 12.66 (+0.22), AMGN: 161.10 (+4.51), ANAC: 99.06 (-0.14)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Regarding the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share
BusinessWire - Thu May 19, 12:33PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Anacor Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Pfizer, Inc.
BusinessWire - Wed May 18, 3:28PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" (NASDAQ: ANAC) concerning the merger with Pfizer, Inc. Under the terms of the agreement, valued at approximately $5.2 billion, Anacor shareholders will only receive $99.25 in cash per share held.
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Ryan & Maniskas, LLP Announces Investigation of Anacor Pharmaceuticals, Inc.
PR Newswire - Wed May 18, 9:41AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company" (NASDAQ: ANAC) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Pfizer Inc. in a transaction valued at approximately $5.2 billion.
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Tue May 17, 4:32PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company" (Nasdaq: ANAC) relating to the proposed buyout of the Company by Pfizer Inc.
ANAC: 99.06 (-0.14)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share -- ANAC
PR Newswire - Tue May 17, 1:44PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Block & Leviton LLP Investigates Anacor Pharmaceuticals Inc., Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Pfizer Inc.
PR Newswire - Tue May 17, 12:26PM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Anacor Pharmaceuticals Inc. ("Anacor" or the "Company" (NASDAQ: ANAC) concerning the proposed acquisition of the Company by Pfizer Inc. ("Pfizer" in an all-cash transaction.
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
Sweta Killa - Zacks Investment Research - Tue May 17, 10:40AM CDT
Pfizer struck a deal to acquire the skin drug maker Anacor Pharmaceuticals for $5.2 billion that sent biotech ETFs higher.
AGN: 240.59 (+2.58), PBE: 39.33 (+0.55), SBIO: 23.62 (-0.02), FBT: 93.72 (+0.78), XBI: 57.59 (+0.52), PFE: 36.12 (+0.35), BBH: 108.48 (+1.82), IBB: 271.13 (+3.29), ANAC: 99.06 (-0.14)
Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio
Arpita Dutt - Zacks Investment Research - Tue May 17, 7:13AM CDT
Pfizer (PFE) maintained its 2016 guidance but expects the deal to be earnings dilutive in 2017 and accretive thereafter.
MDVN: 62.10 (-0.64), AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), BMY: 75.28 (+1.20)
Hercules Provides Portfolio Update for Q2 2016 and Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy
BusinessWire - Tue Jul 05, 10:34AM CDT
--Over $6.0 Billion in Total Debt Commitments Milestone achieved (since inception December 2003)
CPXX: 30.24 (-0.01), HTGC: 12.50 (+0.03), GCI: 13.81 (+0.43), PFE: 36.12 (+0.35), JAZZ: 139.88 (+1.40), ANAC: 99.06 (-0.14), RLOC: 4.56 (-0.01), EACQ: 9.90 (-0.01)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), NVAX: 7.62 (+0.16), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), EXEL: 8.15 (+0.01)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Stock Market News for May 23, 2016
Zacks Equity Research - Zacks Investment Research - Mon May 23, 9:10AM CDT
Benchmarks closed in positive territory on Friday following speculations that indications of a Fed rate hike signal that the economy may be strengthening
TSLA: 216.78 (+0.84), HD: 134.34 (+3.18), FB: 117.24 (+1.39), PFE: 36.12 (+0.35), WMT: 73.84 (+0.31), INTC: 34.00 (+0.80), GS: 150.38 (+3.38), IBM: 154.46 (+1.86), AMAT: 24.93 (+0.64), TGT: 71.31 (+1.22), ANAC: 99.06 (-0.14), GOOGL: 717.78 (+10.52), FL: 57.41 (+2.06), BRK.B: 143.65 (+1.74), AAPL: 96.68 (+0.74)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc.
BusinessWire - Fri May 20, 9:10PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company"
(Nasdaq: ANAC) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer". PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into Whether the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share is Fair to Shareholders
BusinessWire - Fri May 20, 3:43PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
ANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Anacor Pharmaceuticals, Inc. (ANAC) Over the Proposed Sale of the Company to Pfizer Inc.
BusinessWire - Fri May 20, 1:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"
(Nasdaq:ANAC) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $5.2 billion. PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 62.10 (-0.64), TTPH: 4.49 (+0.11), TRVN: 7.13 (+0.19), ADRO: 12.66 (+0.22), ANAC: 99.06 (-0.14)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.40 (+0.08), ARLZ: 3.61 (+0.05), ANAC: 99.06 (-0.14), ATHX: 2.29 (+0.05)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc. -ANAC
PR Newswire - Thu May 19, 9:10PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company"
(Nasdaq- ANAC-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer". PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 62.10 (-0.64), TRVN: 7.13 (+0.19), TTPH: 4.49 (+0.11), VRTX: 88.96 (-1.09), ADRO: 12.66 (+0.22), AMGN: 161.10 (+4.51), ANAC: 99.06 (-0.14)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Regarding the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share
BusinessWire - Thu May 19, 12:33PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Anacor Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Pfizer, Inc.
BusinessWire - Wed May 18, 3:28PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor"
(NASDAQ: ANAC) concerning the merger with Pfizer, Inc. Under the terms of the agreement, valued at approximately $5.2 billion, Anacor shareholders will only receive $99.25 in cash per share held. PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Ryan & Maniskas, LLP Announces Investigation of Anacor Pharmaceuticals, Inc.
PR Newswire - Wed May 18, 9:41AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"
(NASDAQ: ANAC) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Pfizer Inc. in a transaction valued at approximately $5.2 billion. PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Tue May 17, 4:32PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"
(Nasdaq: ANAC) relating to the proposed buyout of the Company by Pfizer Inc. ANAC: 99.06 (-0.14)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share -- ANAC
PR Newswire - Tue May 17, 1:44PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Block & Leviton LLP Investigates Anacor Pharmaceuticals Inc., Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Pfizer Inc.
PR Newswire - Tue May 17, 12:26PM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Anacor Pharmaceuticals Inc. ("Anacor" or the "Company"
(NASDAQ: ANAC) concerning the proposed acquisition of the Company by Pfizer Inc. ("Pfizer" in an all-cash transaction. PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14)
Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
Sweta Killa - Zacks Investment Research - Tue May 17, 10:40AM CDT
Pfizer struck a deal to acquire the skin drug maker Anacor Pharmaceuticals for $5.2 billion that sent biotech ETFs higher.
AGN: 240.59 (+2.58), PBE: 39.33 (+0.55), SBIO: 23.62 (-0.02), FBT: 93.72 (+0.78), XBI: 57.59 (+0.52), PFE: 36.12 (+0.35), BBH: 108.48 (+1.82), IBB: 271.13 (+3.29), ANAC: 99.06 (-0.14)
Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio
Arpita Dutt - Zacks Investment Research - Tue May 17, 7:13AM CDT
Pfizer (PFE) maintained its 2016 guidance but expects the deal to be earnings dilutive in 2017 and accretive thereafter.
MDVN: 62.10 (-0.64), AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), BMY: 75.28 (+1.20)
